{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T09:31:53Z","timestamp":1782034313848,"version":"3.54.5"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"Supplement_4","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,26]]},"abstract":"Abstract<\/jats:title>\n \n Purpose<\/jats:title>\n The aim of this study was to investigate the influence of CYP2D6 functionality on metabolic abnormalities in patients prescribed aripiprazole.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n A retrospective cohort review was conducted in patients who had CYP2D6 genotyping and an oral prescription for aripiprazole. Primary outcomes were changes in metabolic parameters from baseline based on CYP2D6 genotype\u2013based phenotype. Patients concurrently taking medications that cause CYP2D6 inhibition were classified as phenoconverters and were categorized as poor metabolizers in subanalyses. Index and post-aripiprazole (after either initiation or dose modification) data were abstracted from the electronic medical record for the following endpoints: body mass index (BMI), blood glucose, glycated hemoglobin, low-density lipoprotein (LDL), triglycerides, and total cholesterol.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n In multivariate mixed-effects analysis of 1,562 patients, the genotype-based phenotype cohort had no significant differences. A marginal difference in triglyceride levels was observed between poor metabolizers and normal metabolizers (\u03b2 = 23.42; range, \u20134.9 to 51.73; P = 0.11). Findings were similar between poor metabolizers and normal metabolizers when evaluating outcomes encompassing phenoconversion, although poor metabolizers had an increased mean change in LDL levels (\u03b2 = 10.04; range, 1.46 to 18.61; P &lt; 0.05) and had a decreased mean change in BMI (\u03b2 = \u20130.34; range, \u20130.72 to 0.04; P = 0.08); however, these differences were not statistically significant.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n This study suggests that the incidence of metabolic abnormalities beyond LDL may not be higher in CYP2D6 poor metabolizers compared to normal metabolizers. Further research is needed to investigate clinically meaningful outcomes in relation to CYP2D6 and aripiprazole.<\/jats:p>\n <\/jats:sec>","DOI":"10.1093\/ajhp\/zxaf345","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T12:52:36Z","timestamp":1765284756000},"page":"S2976-S2983","source":"Crossref","is-referenced-by-count":1,"title":["Aripiprazole and\n CYP2D6<\/i>\n : A retrospective cohort study evaluating the impact of phenotype on metabolic abnormalities"],"prefix":"10.1093","volume":"83","author":[{"given":"Brian R","family":"Meissner","sequence":"first","affiliation":[{"name":"Sanford Medical Center Fargo , Sanford Health, Fargo, ND ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatme","family":"Younes","sequence":"additional","affiliation":[{"name":"Sanford Medical Center Fargo , Sanford Health, Fargo, ND ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5401-5318","authenticated-orcid":false,"given":"Amanda","family":"Massmann","sequence":"additional","affiliation":[{"name":"Sanford Imagenetics, Sanford Health, Sioux Falls, SD, and Department of Internal Medicine, University of South Dakota School of Medicine , Vermillion, SD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1351-9972","authenticated-orcid":false,"given":"Max","family":"Weaver","sequence":"additional","affiliation":[{"name":"Sanford Imagenetics, Sanford Health , Sioux Falls, SD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5089-9286","authenticated-orcid":false,"given":"Natasha J","family":"Petry","sequence":"additional","affiliation":[{"name":"Sanford Imagenetics, Sanford Health, Sioux Falls, SD, and College of Health and Human Sciences, North Dakota State University , Fargo, ND ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"issue":"2","key":"2026052609211763800_zxaf345-B1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000445802","article-title":"Genetics of common antipsychotic-induced adverse effects","volume":"2","author":"MacNeil","year":"2016","journal-title":"Mol Neuropsychiatry"},{"key":"2026052609211763800_zxaf345-B2"},{"issue":"8","key":"2026052609211763800_zxaf345-B3","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.2174\/1570159X15666170413115754","article-title":"Aripiprazole, a drug that displays partial agonism and functional 
selectivity","volume":"15","author":"Tuplin","year":"2017","journal-title":"Curr Neuropharmacol"},{"issue":"10202","key":"2026052609211763800_zxaf345-B4","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"2026052609211763800_zxaf345-B5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"2026052609211763800_zxaf345-B6","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/bcpt.12960","article-title":"Influence of 2D6, 3A4, 3A5 and 1 polymorphisms on pharmacokinetics and safety of aripiprazole in healthy volunteers","volume":"122","author":"Belmonte","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2026052609211763800_zxaf345-B7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jpsychires.2024.04.001","article-title":"Influence of CYP2C19 and CYP2D6 on side effects of aripiprazole and risperidone: a systematic review","volume":"174","author":"de Brabander","year":"2024","journal-title":"J Psychiatr Res"},{"issue":"2","key":"2026052609211763800_zxaf345-B8","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s12325-020-01566-w","article-title":"Metabolic effects of aripiprazole and olanzapine multiple-dose treatment in a randomised crossover clinical trial in healthy volunteers: association with pharmacogenetics","volume":"38","author":"Koller","year":"2021","journal-title":"Adv Ther"},{"issue":"5","key":"2026052609211763800_zxaf345-B9","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/S2215-0366(19)30088-4","article-title":"Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study","volume":"6","author":"Jukic","year":"2019","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"2026052609211763800_zxaf345-B10","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/bcpt.12960","article-title":"Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 polymorphisms on pharmacokinetics and safety of aripiprazole in healthy volunteers","volume":"122","author":"Belmonte","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"2026052609211763800_zxaf345-B11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1089\/cap.2020.0058","article-title":"CYP2D6 phenotype influences aripiprazole tolerability in pediatric patients with mood disorders","volume":"31","author":"Jallaq","year":"2021","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"2026052609211763800_zxaf345-B12","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41431-023-01347-3","article-title":"Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics","volume":"32","author":"Beunk","year":"2024","journal-title":"Eur J Hum Genet"},{"key":"2026052609211763800_zxaf345-B13","volume-title":"Medical Genetics Summaries","author":"Dean","year":"2012"},{"issue":"16","key":"2026052609211763800_zxaf345-B14","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1093\/ajhp\/zxae083","article-title":"Implementation of CYP2C19 and CYP2D6 genotyping to guide antidepressant use in a large rural health system","volume":"81","author":"Petry","year":"2024","journal-title":"Am J Health-Syst Pharm"},{"issue":"12","key":"2026052609211763800_zxaf345-B15","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2217\/pgs-2019-0043","article-title":"Implementation of wide-scale pharmacogenetic testing in primary care","volume":"20","author":"Petry","year":"2019","journal-title":"Pharmacogenomics"},{"issue":"9","key":"2026052609211763800_zxaf345-B16","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2217\/pgs-2023-0016","article-title":"Congruence rates for pharmacogenomic noninterruptive alerts","volume":"24","author":"Mills","year":"2023","journal-title":"Pharmacogenomics"},{"issue":"1-2","key":"2026052609211763800_zxaf345-B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14622416.2025.2479409","article-title":"Reinterpretation of pharmacogenomic phenotypes after combinatorial psychiatric testing","volume":"26","author":"Cung","year":"2025","journal-title":"Pharmacogenomics"},{"issue":"5","key":"2026052609211763800_zxaf345-B18","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1002\/cpt.1613","article-title":"Preemptively precise: returning and updating pharmacogenetic test results to realize the benefits of preemptive testing","volume":"106","author":"Haidar","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"2026052609211763800_zxaf345-B19","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.3390\/jpm11111051","article-title":"Impact of updating pharmacogenetic results: lessons learned from the PREDICT Program","volume":"11","author":"Liu","year":"2021","journal-title":"J Pers Med"},{"issue":"1","key":"2026052609211763800_zxaf345-B20","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/cts.12692","article-title":"Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group","volume":"13","author":"Caudle","year":"2020","journal-title":"Clin Transl Sci"},{"issue":"3","key":"2026052609211763800_zxaf345-B21","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/cpt.2354","article-title":"How to integrate CYP2D6 phenoconversion into clinical pharmacogenetics: a tutorial","volume":"110","author":"Cicali","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"2026052609211763800_zxaf345-B22","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/bcp.12441","article-title":"Addressing phenoconversion: the Achilles\u2019 heel of personalized medicine","volume":"79","author":"Shah","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"2026052609211763800_zxaf345-B23","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1080\/17425255.2022.2160317","article-title":"CYP2D6 pharmacogenetics and phenoconversion in personalized medicine","volume":"18","author":"Nahid","year":"2022","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"2026052609211763800_zxaf345-B24","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/cpt.1768","article-title":"A scoping review of the evidence behind cytochrome P450 2D6 isoenzyme inhibitor classifications","volume":"108","author":"Cicali","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"2026052609211763800_zxaf345-B25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1177\/2045125316629071","article-title":"Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant","volume":"6","author":"Patel","year":"2016","journal-title":"Ther Adv Psychopharmacol"},{"issue":"5","key":"2026052609211763800_zxaf345-B26","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/MOL.0000000000000536","article-title":"Sex differences in metabolism and cardiometabolic disorders","volume":"29","author":"Chella Krishnan","year":"2018","journal-title":"Curr Opin Lipidol"},{"issue":"5","key":"2026052609211763800_zxaf345-B27","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1093\/schbul\/sbae205","article-title":"Metformin for the prevention of antipsychotic-induced weight gain: guideline development and consensus validation","volume":"51","author":"Carolan","year":"2025","journal-title":"Schizophr Bull"},{"key":"2026052609211763800_zxaf345-B28","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.schres.2024.07.007","article-title":"Aripiprazole dose associations with metabolic adverse effect: results from a longitudinal study","volume":"270","author":"Piras","year":"2024","journal-title":"Schizophr Res"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxaf345\/65818725\/zxaf345.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/Supplement_4\/S2976\/65818725\/zxaf345.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/Supplement_4\/S2976\/65818725\/zxaf345.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T13:21:22Z","timestamp":1779801682000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/83\/Supplement_4\/S2976\/8374809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":28,"journal-issue":{"issue":"Supplement_4","published-online":{"date-parts":[[2025,12,9]]},"published-print":{"date-parts":[[2026,5,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxaf345","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,1]]},"published":{"date-parts":[[2025,12,9]]}}}